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Abstract
Background: New systemic chemotherapy agents have improved prognosis in patients with colorectal liver
metastases (CLM), but some of them damage the liver parenchyma and ultimately increase postoperative morbidity
and mortality after liver resection. The aims of our study were to determine the degree of hemodynamic and
pathological liver injury in CLM patients receiving preoperative chemotherapy and to identify an association
between these injuries and postoperative complications after liver resection.
Methods: This is a prospective descriptive study of patients with CLM receiving preoperative chemotherapy before
curative liver resection from November 2013 to June 2014. All patients had preoperative elastography and hepatic
hemodynamic evaluation. We analyzed clinical preoperative data and postoperative outcomes after grouping the patients
by chemotherapy type, development of sinusoidal obstructive syndrome (SOS), and development of major complications.
Results: Eleven from the 20 patients included in the study received preoperative oxaliplatin-based chemotherapy (OBC).
Nine patients had SOS at pathological analysis and five patients developed major complications. Patients receiving
preoperative OBC had higher values of hepatic venous pressure gradient (HVPG) and developed more SOS and major
complications. Patients developing SOS had higher values of HVPG and developed more major complications. Patients
with major complications had higher values of HVPG, and patients with a HVPG of 5 mmHg or greater had more major
complications than those under 5 mmHg (20 vs 80%, p = 0.005).
Conclusions: OBC and SOS impair liver hemodynamics in CLM patients. An increase in major complications after liver
resection in these patients develops at subclinical HVPG levels.
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Background
Colorectal carcinoma (CRC) is one of the most common
cancers in the Western world, and approximately 50% of
patients develop liver metastases [1]. The standard treat-
ment for resectable colorectal liver metastases (CLM) is
complete surgical resection, which offers a 5-year sur-
vival rate up to 58% [2]. In the last years, new systemic
chemotherapy agents have improved the rates of
complete resection and survival in patients with unre-
sectable CLM at the time of diagnosis [3]. However,
some of these agents damage the liver parenchyma and
increase postoperative morbidity and mortality [4].
The main patterns of liver injury from systemic che-
motherapeutic agents are chemotherapy-associated stea-
tohepatitis and sinusoidal obstructive syndrome (SOS),
which are associated with irinotecan and oxaliplatin
respectively [4, 5]. Liver damage remains asymptomatic
in the majority of cases, but severe oxaliplatin-induced
SOS cases can evolve into non-cirrhotic portal hyperten-
sion (PHT) and ultimately complicate the safe applica-
tion of subsequent therapies [4, 6]. Recently, several
studies have found promising biochemical markers to
diagnose the presence of sinusoidal obstruction, but
these biomarkers could not quantify the degree and
extent of hepatic injury nor diagnose the presence of
clinical or subclinical PHT. Moreover, none of these
studies measured the direct hemodynamic effects of
chemotherapy-induced hepatic toxicity or quantified its
related postoperative risks [7, 8].
Therefore, the aims of our study were to determine
the hemodynamic impairment, liver stiffness, and patho-
logical liver injury in patients with CLM who received
preoperative chemotherapy and to identify a possible
link between these injuries and the postoperative com-
plications after liver resection.
Methods
This is a prospective descriptive study of patients with
CLM who received preoperative chemotherapy and
underwent liver resection with curative aim between
November 2013 and June 2014 at our Liver Surgery and
Transplantation Unit. As per the study, all patients had
hepatic elastography and hemodynamic measurements
to assess for liver fibrosis and hepatic venous pressure
gradient (HVPG) before undergoing liver resection. We
excluded patients with any pre-existing liver condition
(e.g., cirrhosis, chronic liver disease) and patients with
previous liver resection. The hospital ethics committee
approved this study, and all included patients gave their
informed consent to participate in the study when
surgery for CLM was proposed.
We obtained all demographical, clinical, and patho-
logic data from our prospective CLM database and
patients’ charts. Preoperative chemotherapy (defined as
received within the 6 months before CLM surgery) regi-
men was decided by the referring oncologist based on
institutional protocols and routine practice. Patients
underwent protocolized preoperative CLM staging
(imaging and blood tests including tumor markers and
liver function tests), postoperative care, and follow-up as
previously described [9]. All patients were appointed to
the Liver Surgery and Transplantation Clinic 1 month
after discharge to record and grade the presence of com-
plications during this postoperative period according to
the Clavien-Dindo classification [10]. As per our Institu-
tion policy [9], CLM diagnosed before, during, or within
90 days of CRC resection were classified as synchronous
and those CLM diagnosed at least 90 days after CRC
resection were classified as metachronous. We defined
major hepatectomy as the resection of three or more
liver segments.
HVPG was obtained in all patients through a standard
transjugular approach under local anesthesia. Briefly, we
placed an 8-Fr venous catheter introducer in the right
internal jugular vein with the Seldinger technique,
measured wedge and free hepatic venous pressures, and
calculated HVPG as the difference between them. We
defined HVPG as normal when it was under 5 mmHg,
as subclinical PHT when HVPG was between 6 and
9 mmHg, and as clinically significant PHT when HVPG
was 10 mmHg or more regardless of the presence of
clinical signs of PHT [11].
Elastography was obtained in all patients lying in the
dorsal decubitus position with the right arm in maximal
abduction. The measures were performed on the right
lobe of the liver through intercostal spaces and values
expressed in kilopascals (kPa) as previously described
[12]. We defined normal elastography as stiffness under
7 kPa, presence of fibrosis when stiffness was between 7
and 14 kPa, and cirrhosis when stiffness was over
14 kPa.
Histological analysis was performed by a local experi-
enced liver pathologist who was unaware of the
treatment modality. Surgical specimens were processed
and sampled as routinely according internal cut-up pro-
tocols. The number of tumors, size, distance to the
transection margin, and capsular involvement were
recorded, as well as the presence, distribution and
approximate percentage of reticulated areas of conges-
tion or hemorrhage, or parenchymal nodularity. At least
one sample of non-tumoral liver more than 2 cm distant
from the tumor was taken, with representation of the
macroscopic lesions if present. The microscopic
evaluation of the lesions on the background parenchyma
was based on hematoxylin-eosin, Masson’s trichrome,
and reticulin stains. SOS was diagnosed and graded
according to previously published criteria [13]. Briefly,
the diagnosis of SOS was made when sinusoidal
Pelegrina et al. World Journal of Surgical Oncology  (2017) 15:224 Page 2 of 8
dilatation, sinusoidal congestion, and hepatocellular
atrophy coexisted. Other lesions such as endothelial rup-
ture with erythrocyte extravasation at the Disse space,
central vein obliteration, nodular regenerative hyperpla-
sia, and perisinusoidal fibrosis were also recorded.
Finally, the degree of steatosis was assessed if present
according to previous published criteria [14].
The patients were classified into different groups
according to whether they had or not received
oxaliplatin-based chemotherapy (OBC) (thus, investi-
gated and control groups respectively), according to the
presence of SOS at the pathology exam, and whether
they had major postoperative complications (defined as
grade III or higher in the Clavien-Dindo classification
during the 30 days after the CLM operation).
All quantitative variables were tested with the
Shapiro-Wilk test to ascertain normal distributions.
We described quantitative variables as mean (standard
deviation) or as median (interquartile range) when
distribution was not normal. Qualitative variables
were expressed as number and % and compared with
chi-square test. We compared groups with Student’s t
test, Mann-Whitney U test or Fisher’s exact test as
appropriate. A p value under 0.05 was considered
statistically significant. All statistical calculations were
performed with the “Statistical Package for the Social




Twenty patients fulfilled the inclusion criteria during the
study period. Demographic and preoperative data of the
patients are shown on Tables 1 and 2. Eleven patients
(55%) received preoperative OBC, with two of these
patients receiving also biological agents (one panitumu-
mab and another one bevacizumab). The median num-
ber of cycles of chemotherapy per patient was 6 (range
1–12). In three patients of the series, prothrombin time
was under 80%, and only four patients had platelets
under 150,000, although all patients had platelets over
100,000. The majority of patients had normal HVPG
values, and no patients had significant PHT. Three
patients (15%) had liver stiffness over 7 kPa, but no
patients had stiffness values over 9 kPa.
Results by chemotherapy type
Eight (73%) of the 11 patients receiving preoperative
OBC showed SOS lesions in the non-neoplastic hepatic
parenchyma. When comparing both groups, patients
receiving preoperative OBC had significantly higher
values of HVPG and higher SOS development but
similar hospital stay, liver stiffness, platelets, and PT.
Patients who received preoperative OBC had more
major complications than the ones not receiving OBC,
with all five patients with major complications receiving
OBC (Table 3).
Histological findings
Nearly 50% of overall patients in our series presented
with histological abnormalities leading to the diagnosis
of SOS, all of them having received preoperative OBC.
Patients with SOS had higher values of HVPG and had
received more chemotherapy cycles, but they had similar
liver stiffness, platelets, PT, length of hospital stay, and
major complications than those patients without SOS
(Table 4).
Analysis of complications
Median length of hospital stay was 7 days (range 6–10),
and overall complication rate was 70%. The majority of
the major complications were basically general (intraab-
dominal collections, pleural effusions), although two of
them were related to biliary leaks that required reopera-
tion However, the majority of patients’ complications
(64%) were graded as I–II, and there were no patients
with IV or higher grade complications. Four (80%) of the
five patients who presented with major complications
had SOS on the pathologic analysis. Patients with
complications had similar values of HVPG, PT, liver
stiffness, platelets, and length of hospital stay than the
patients without complications (data not shown). How-
ever, patients with major complications had higher
values of HVPG and lower PT values but similar liver
Table 1 Patients characteristics (n = 20)
Sex (male:female) 13:7
Age (years) (mean ± SD) 63.35 ± 11.49
Body mass index (kg/m2) (median, range) 25 (22.9–29.5)
ASA grade (n, %)
I–II 12 (60%)
III–IV 8 (40%)
Platelets (mean ± SD) 208,600 ± 73,650
Prothrombin activity percentage (mean ± SD) 94.47 ± 10.44
HVPG (mmHg) (mean ± SD) 3.80 ± 1.67
Elastography (kPa) (mean ± SD) 5.41 ± 1.67
No. of metastases (mean ± SD) 2.26 ± 1.94






ASA American Society of Anesthesiologists, HVPG hepatic venous
pressure gradient
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stiffness, platelets, and length of hospital stay than the
patients without major complications (Table 5). Also,
major resections were not a factor that was statistically
associated with more complications (although nearly
significant), age, or comorbidities (defined by the ASA
grade). When performing a ROC curve, 4.25 mmHg was
the HVPG value that gave better sensitivity and specifi-
city (80 and 80% respectively) for major complications,
and the AUC was 0.867 (p = 0.016). In this direction,
patients with a HVPG of 5 mmHg or greater had more
major complications than those under 5 mmHg (20 vs
80%, p = 0.005).
Discussion
The appearance of new systemic chemotherapy agents
has increased resectability and survival rates in patients
with CLM, but some of these agents damage the liver
parenchyma and increase postoperative morbidity and
mortality [4, 5, 15]. One of the most well-known liver
injury patterns is oxaliplatin-induced SOS, which can
evolve into non-cirrhotic PHT in serious cases [6]. How-
ever, no studies have shown the hemodynamic effects of
chemotherapy-induced hepatic toxicity by direct meas-
urement of the vascular pressures by transjugular
hemodynamic procedure of the liver, or quantified the
Table 2 Hemodynamic measurements, elastography, laboratory findings, chemotherapy, SOS, and complications
Patient HVPG Elastography Platelets PT (%) Chemotherapy (cycles) OBC SOS Complications
1 4.50 6.80 336,000 100 FOLFOX [6] Yes Yes 0
2 6.50 N/A 157,000 100 FOLFOX [8] Yes Yes I
3 2.00 N/A 135,000 76 Capecitabine [2] – – 0
4 4.00 N/A 105,000 98 FOLFOX [9] – Yes I
5 7.00 7.90 150,000 95 FOLFOXIRI [8] Yes Yes IIIA
6 6.00 8.40 136,000 89 FOLFOX [6] Yes Yes IIIA
7 2.00 N/A 196,000 99 FOLFOX + FOLFIRI [12] – – I
8 2.50 3.80 192,000 100 FOLFOX [4] Yes – I
9 2.50 4.70 199,000 100 Capecitabine [1] – – 0
10 1.50 N/A 197,000 100 FOLFOX + bevacizumab [7] – – I
11 5.00 N/A 191,000 100 FOLFOX [4] Yes Yes IIIB
12 2.50 5.20 274,000 100 Capecitabine [6] – – 0
13 4.00 4.40 157,000 100 FOLFOX [5] Yes Yes IIB
14 4.00 6.10 135,000 100 FOLFOX [3] – – I
15 4.00 7.60 283,000 100 FOLFOX [6] Yes – I
16 2.50 3.60 215,000 92 FOLFIRI + cetuximab [6] – – I
17 6.00 4.50 291,000 78 TOMOX [6] Yes Yes IIIA
18 2.00 5.20 157,000 100 FOLFOX + TOMOX + panitumumab [8] – – 0
19 4.5 4.00 331,000 100 FOLFOX [5] Yes Yes 0
20 3 3.50 335,000 62.50 XELOX [5] Yes – IIIB
N/A not available






HVPG (mmHg)a mean (SD) 2.56 (.88) 4.82 (1.44) 0.001
Elastography (kPa)a mean (SD) 4.96 (.91) 5.66 (1.98) 0.478
Platelets (log)a mean (SD) 5.24 (.13) 5.34 (.16) 0.127
PT (%)b median; (IQR) 100.0 (98.0, 100.0) 100 (89.0, 100.0) 0.998
Length of hospital stay (days)b Median (IQR) 7.0 (5.0, 9.0) 8.0 (7.0, 10.0) 0.412
SOS development n (%)c 1 (11.1) 8 (72.7) 0.010
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association between these hemodynamic effects and
postoperative complications [7, 8].
Oxaliplatin is a systemic chemotherapy agent that pre-
vents cell division and replication by crosslinking DNA
strands. In the liver, oxaliplatin damages mainly the
sinusoidal endothelial cells and causes SOS, which
ultimately decreases the hepatic functional reserve and
increases the risk of bleeding during surgery [4, 5].
Several studies have intended to predict SOS based on
blood and serum parameters like platelet count,
aspartate aminotransferase, gamma glutamyl transferase,
alkaline phosphatase, and aspartate aminotransferase to
platelet ratio index. However, these biomarkers have not
been proved useful to quantify the degree and extent of
hepatic injury, and still no large studies have validated
them as a reliable indicator of sinusoidal damage [7, 8].
On the other hand, there are no studies focused on the
presence of clinical or subclinical PHT induced by OBC,
something that only direct measurement of liver
hemodynamic parameters can accurately diagnose [11].
Our study showed that patients receiving preoperative
OBC had higher values of HVPG when compared to
patients not receiving OBC and also that SOS develop-
ment was associated with receiving OBC (especially
when the number of chemotherapy cycles increased).
This latter observation is consistent with previous
studies showing a clear link between OBC and the
development of SOS [4, 6, 16, 17]. On the other hand,
the increase of HVPG in patients receiving OBC or
developing SOS clearly shows that OBC impairs liver
pathology and hemodynamic parameters. This observa-
tion favors the logical and already postulated pathogen-
ical hypothesis that preoperative OBC would lead to
sinusoidal obstruction and increased intrahepatic resist-
ance and would subsequently increase HVPG [6, 17].
Several studies have highlighted the increase of post-
operative morbidity and mortality in CLM patients
treated with chemotherapy drugs and the important role
of a proper operative timing given the frequent attenu-
ation of liver injury after stopping the systemic chemo-
therapy agent [18–20]. The ideal situation would be to
predict the increased postoperative risk before surgery
by diagnosing SOS in patients treated with OBC. To this
objective, some authors have proposed to perform
preoperative percutaneous or transjugular liver biopsies
or even a diagnostic laparoscopy to rule out significant
liver alterations and select the best possible therapeutic
strategy for each patient [5, 18, 19]. However, as SOS
histological lesions may be focal or even patchy, these
alternatives remain controversial because of the risks of
sampling error and subsequent underdiagnosis of
sinusoidal lesions. Lately, Nakano et al. have identified
several preoperative factors associated to sinusoidal
damage (6 or more cycles of oxaliplatin, abnormal pre-
operative liver function tests, increased indocyanine
green retention rate, and female sex) that can help to get
the diagnosis in the preoperative setting [20]. In our
study, however, we could not find differences in the pre-
operative biochemical parameters between patients
developing SOS or not, nor did we find differences in
Table 4 Comparison of patients with and without SOS
No SOS (n = 11) SOS (n = 9) p value
HVPG (mmHg)a mean (SD) 2.59 (.80) 5.28 (1.12) <0.001
Elastography (kPa)a mean (SD) 4.96 (1.40) 6.00 (1.94) 0.266
Platelets (log)a mean (SD) 5.31 (0.13) 5.28 (0.18) 0.698
PT (%)b median (IQR) 100 (92.0, 100) 100 (95.0, 100) 0.882
Length of hospital stay (days)b median (IQR) 7.0 (5.0, 12.0) 8.0 (7.0, 8.0) 0.998




Table 5 Comparison according to the presence of major complications
Absent or minor complications (n = 15) Major complications (n = 5) p value
HVPG (mmHg)a mean (SD) 3.27 (1.36) 5.40 (1.52) 0.008
Elastography (kPa)a mean (SD) 5.14 (1.33) 6.08 (2.44) 0.511
Platelets (log)a mean (SD) 5.29 (0.15) 5.32 (0.17) 0.772
PT (%)b median (IQR) 100 (99.0. 100.0) 89.0 (78.0, 95) 0.033
Length of hospital stay (days)b median (IQR) 7.0 (6.0, 9.0) 8.5 (7.0, 10.0) 0.445
aStudent’s t tests
bMann-Whitney U-test
Pelegrina et al. World Journal of Surgical Oncology  (2017) 15:224 Page 5 of 8
the major complication rate between patients developing
SOS. Nevertheless, the specific aim of our study and the
limited number of patients included in it can easily
explain these observations because we designed our
study towards successfully finding differences in
hemodynamic alterations but not towards finding
differences in the preoperative biochemical parameters
or in major complications. Despite this limitation, that
adds to not being able to prove that increases in HVPG
are the main cause for postoperative complications, we
believe that the large amount of existing studies proving
the relation between SOS development and the subse-
quent alteration of preoperative biochemical parameters
(with increased complications) makes it unnecessary to
challenge this well-studied fact and still keeps the
validity of our study.
PHT becomes clinically significant when HVPG rises
above 10 mmHg and the patient develops cirrhotic
complications like variceal bleeding, ascites, or
thrombocytopenia [11]. Moreover, several studies on
patients with liver cirrhosis undergoing liver resection
and other surgical procedures have demonstrated the
importance of PHT. In this direction, more than 50% of
cirrhotic patients classified as Child-Pugh A will decom-
pensate after surgery, with subsequent decreased quality
of life and long-term survival [21–23]. Although spleno-
megaly and thrombocytopenia are usually indirect
clinical signs of PHT in cirrhosis or in patients receiving
OBC [6–8], direct hepatic hemodynamic evaluation is
currently the best method to study and diagnose PHT
[11, 24]. To the present one, no study had directly
measured the liver hemodynamic effects of
chemotherapy-induced liver damage or attempted to
correlate their hemodynamic changes with the develop-
ment of complications. In our study, patients with major
complications had higher HVPG than those not develop-
ing major complications, and major complications devel-
oped at lower cutoff HVPG levels than the usually
accepted to define clinically significant PHT in patients
with chronic liver diseases [11, 24]. These interesting
new findings suggest a causal association between OBC-
induced liver hemodynamic impairment and major com-
plications but also show that the development of major
complications in CLM patients receiving preoperative
OBC starts at earlier HVPG levels than those universally
accepted as clinically relevant in patients with chronic
liver diseases. Although the design of our study cannot
elucidate the cause for this earlier manifestation of initial
hemodynamic impairment, we hypothesize that OBC-
related liver injury would cause significant liver damage
and an increase in major postoperative complications
because of the lack of compensatory mechanisms against
the hemodynamic disturbances that only develop in
patients with chronic liver diseases. More important,
however, it is the fact that clinicians taking care of CLM
patients receiving OBC should be aware of the develop-
ment of this early significant hemodynamic impairment
and specifically look for it in advance because of its
severe clinical consequences.
Elastography has been advocated to be a useful tool to
diagnose the degree of liver fibrosis and PHT through
liver stiffness measurement, although several factors
including sex, liver inflammation, cholestasis, hepatocel-
lular carcinoma, liver congestion, and disease etiology
may influence its results [12, 25–27]. One of the few
studies about liver elastography in patients with CRC
has shown that liver stiffness increases within 48 h after
starting OBC and normalizes within 2 weeks after treat-
ment in most cases [28]. In our study, we could not find
any difference in liver stiffness when comparing by
whether the patient had received OBC, developed SOS
or suffered major complications. The most likely reason
for this lack of association is that, as observed in other
studies, elastography results only correlate with those
obtained by hepatic hemodynamic evaluation for HVPG
above 10 mmHg [12, 25–27]. Also, elastography results
are mainly affected by the amount of liver fibrosis but
not by the degree of sinusoidal obstruction, a fact that is
better studied with direct liver hemodynamic measure-
ments [11, 29]. We believe that in order to find some
differences in liver stiffness, our study should have
included patients with higher hemodynamic impairment,
something that was not done because of the exploratory
nature of our study. However, this limitation needs to be
taken into account when designing further studies
specifically aiming to find the value of elastography to
predict chemotherapy-induced liver injury.
Even though this is the first study to directly analyze
liver hemodynamic parameters in CLM patients
receiving preoperative chemotherapy, we acknowledge
that our study had some limitations. Small sample size
is probably the most obvious and important one, but
this limitation comes from the study being necessarily
an exploratory analysis because no similar studies
existed and because potential complications that can
derive from direct hepatic hemodynamic measurement
advised against a large preliminary study [29].
Nevertheless, we feel that this is a minor limitation
because sample size accounted for not finding
differences in some variables that have extensively
described by other studies but that were not the pri-
mary objective of our study. In this sense, future similar
studies should aim to enroll more patients and include
more heterogeneous patients (e.g., patients with previ-
ous chronic liver diseases or with longer chemotherapy
treatments) in order to enable stratification and ascer-
tain the effect of other preoperative characteristics in
the postoperative results.
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Other limitations that can be found in our study
include the concern for overdiagnosis of SOS after OBC,
which derives from the fact that nearly 75% of patients
receiving OBC were histologically diagnosed with SOS,
and also the fact that HVPG measurement was done
only after receiving chemotherapy, raising the concern
that maybe there were some prior alterations in HVPG
before chemotherapy. We feel that further studies with
different designs adapted to these limitations can help to
solve these questions that our current design study
cannot answer.
Conclusions
To conclude, our preliminary study confirmed the associ-
ation between OBC and SOS in CLM patients and showed
that OBC-induced SOS impairs liver hemodynamics,
moreover describing that major complications in these
patients start to develop at lower HVPG levels than those
universally accepted as clinically relevant in patients with
chronic liver diseases. These interesting results should
encourage further analyses to define the effect of other
preoperative characteristics in CLM patients receiving
OBC and thus improve postoperative results.
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